Belpointe Asset Management LLC Increases Holdings in Kenvue Inc. $KVUE

Key Points

• Belpointe Asset Management LLC increased its holdings in Kenvue Inc. by 85.1%, owning 73,661 shares valued at approximately $1.77 million after purchasing an additional 33,864 shares.
• Kenvue's recent quarterly earnings reports a profit of $0.29 per share, slightly exceeding analysts' estimates, although revenues fell short by 4% year-over-year, totaling $3.84 billion.
• Kenvue recently declared a quarterly dividend of $0.2075, raising its annualized dividend to $0.83, which results in a dividend yield of 4.5% despite a payout ratio of 112.16%.

Belpointe Asset Management LLC increased its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 85.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 73,661 shares of the company's stock after purchasing an additional 33,864 shares during the quarter. Belpointe Asset Management LLC's holdings in Kenvue were worth $1,766,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Pittenger & Anderson Inc. bought a new stake in shares of Kenvue during the 1st quarter valued at $30,000. TruNorth Capital Management LLC bought a new stake in shares of Kenvue during the 1st quarter valued at $36,000. Truvestments Capital LLC bought a new stake in shares of Kenvue during the 1st quarter valued at $37,000. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock valued at $39,000 after purchasing an additional 1,287 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich raised its stake in shares of Kenvue by 120.6% during the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock valued at $41,000 after purchasing an additional 929 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Price Performance

KVUE stock traded up $0.18 during mid-day trading on Friday, hitting $19.03. 26,726,491 shares of the stock were exchanged, compared to its average volume of 23,182,142. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The business has a fifty day moving average price of $21.14 and a 200 day moving average price of $22.23. Kenvue Inc. has a 12 month low of $17.15 and a 12 month high of $25.17. The stock has a market capitalization of $36.52 billion, a price-to-earnings ratio of 25.71, a PEG ratio of 2.71 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The company had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same quarter in the previous year, the company posted $0.32 EPS. Kenvue's revenue for the quarter was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. Kenvue's dividend payout ratio is presently 112.16%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of analyst reports. Citigroup decreased their price objective on Kenvue from $24.50 to $22.00 and set a "neutral" rating on the stock in a research note on Tuesday, July 15th. Zacks Research raised Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Canaccord Genuity Group dropped their price objective on Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Royal Bank Of Canada dropped their price objective on Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. Finally, Barclays dropped their price objective on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $24.21.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.